 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Acute Liver Failure in the United States
17 December 2002 | Volume 137 Issue 12 | Page I-24
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States." It is in the 17 December 2002 issue of Annals of Internal Medicine (volume 137, pages 947-954). The authors are G Ostapowicz, RJ Fontana, FV Schiødt, A Larson, TJ Davern, SHB Han, TM McCashland, AO Shakil, JE Hay, L Hynan, JS Crippin, AT Blei, G Samuel, J Reisch, WM Lee, and the U.S. Acute Liver Failure Study Group.
Why did the researchers do this particular study?
Acute liver failure is a potentially deadly condition that affects about 2000 Americans each year. Most often, liver failure develops over a period of years as an insult to the liver (such as alcohol abuse or infection with hepatitis virus) slowly damages it. Less commonly, liver failure is acute, meaning that it occurs over a period of days or weeks. The things that can cause acute liver failure include hepatitis virus infections, drugs, pregnancy, autoimmune disease, and sudden low blood flow to the liver. Little is known about how often each of these things is responsible for acute liver failure in the United States. Information about the causes and outcomes of acute liver failure would be helpful to doctors who care for patients with this condition.
Who was studied?
308 patients with acute liver failure who received care between January 1998 and May 2001 at 1 of 17 U.S. medical centers that specialize in liver disease. All patients were 15 years of age or older.
How was the study done?
Each of the 17 participating centers kept careful records of patients' information, including the cause of the liver failure, physical examination and laboratory findings, and information about how the patients were doing 3 weeks after they first presented to a study center. The researchers used this information to determine the frequency of the various causes of acute liver failure. They also looked for associations among patient characteristics, cause of liver failure, and patient outcomes.
What did the researchers find?
The most frequent causes of acute liver failure were overdose of acetaminophen (an over-the-counter pain and fever medicine), other drug reactions, and hepatitis A or B virus infection. In 17% of cases, the cause was unknown. At 3 weeks, 67% of the patients were alive. Of the patients who were alive at 3 weeks, 29% had undergone a liver transplantation. Survival varied greatly with cause. Of the patients with acetaminophen overdose who had not received a liver transplant, 68% were alive at 3 weeks compared with only 17% who had liver failure of unknown cause. Older age and being in a coma at the time of presentation were also associated with worse outcomes.
What were the limitations of the study?
The patients with acute liver failure at the 17 specialized centers in this study may be different from those who get care at other places.
What are the implications of the study?
In the United States, drugs, particularly acetaminophen, seem to be a more common cause of acute liver disease than hepatitis infection or other conditions. However, this study does not suggest that acetaminophen taken in recommended doses is dangerous to the liver. Among patients with acute liver failure in this study, those with acetaminophen overdose and those who were not in comas fared best.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  P. J. Shaw, P. E. Ganey, and R. A. Roth Tumor Necrosis Factor{alpha} Is a Proximal Mediator of Synergistic Hepatotoxicity from Trovafloxacin/Lipopolysaccharide Coexposure J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 62 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Shaw, A. C. Ditewig, J. F. Waring, M. J. Liguori, E. A. Blomme, P. E. Ganey, and R. A. Roth Coexposure of Mice to Trovafloxacin and Lipopolysaccharide, a Model of Idiosyncratic Hepatotoxicity, Results in a Unique Gene Expression Profile and Interferon Gamma-Dependent Liver Injury Toxicol. Sci., January 1, 2009; 107(1): 270 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Naun Intensive Care of Patients with Acute Liver Failure AAP Grand Rounds, March 1, 2008; 19(3): 32 - 33. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Zimmerman, A. Patat, V. Parks, R. Moirand, and K. Matschke Pharmacokinetics of Sirolimus (Rapamycin) in Subjects With Severe Hepatic Impairment J. Clin. Pharmacol., March 1, 2008; 48(3): 285 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Shaw, M. J. Hopfensperger, P. E. Ganey, and R. A. Roth Lipopolysaccharide and Trovafloxacin Coexposure in Mice Causes Idiosyncrasy-Like Liver Injury Dependent on Tumor Necrosis Factor-Alpha Toxicol. Sci., November 1, 2007; 100(1): 259 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Clay and B. E. Hainline Hyperammonemia in the ICU Chest, October 1, 2007; 132(4): 1368 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gotthardt, C. Riediger, K. H. Weiss, J. Encke, P. Schemmer, J. Schmidt, and P. Sauer Fulminant hepatic failure: etiology and indications for liver transplantation Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_8): viii5 - viii8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P DeSanty and C. M Amabile Antidepressant-Induced Liver Injury Ann. Pharmacother., July 1, 2007; 41(7): 1201 - 1211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Cornwell and R. G. Ulrich Investigating the Mechanistic Basis for Hepatic Toxicity Induced by an Experimental Chemokine Receptor 5 (CCR5) Antagonist Using a Compendium of Gene Expression Profiles Toxicol Pathol, June 1, 2007; 35(4): 576 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Le Minh, K. Klemm, K. Abshagen, C. Eipel, M. D. Menger, and B. Vollmar Attenuation of Inflammation and Apoptosis by Pre- and Posttreatment of Darbepoetin-{alpha} in Acute Liver Failure of Mice Am. J. Pathol., June 1, 2007; 170(6): 1954 - 1963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Gonzalez CYP2E1 Drug Metab. Dispos., January 1, 2007; 35(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Betten, R. B. Vohra, M. D. Cook, M. J. Matteucci, and R. F. Clark Antidote use in the critically ill poisoned patient. J Intensive Care Med, September 1, 2006; 21(5): 255 - 277. [Abstract] [PDF]
|
|
|
|
|
|
C. L. Powell, O. Kosyk, P. K. Ross, R. Schoonhoven, G. Boysen, J. A. Swenberg, A. N. Heinloth, G. A. Boorman, M. L. Cunningham, R. S. Paules, et al. Phenotypic Anchoring of Acetaminophen-Induced Oxidative Stress with Gene Expression Profiles in Rat Liver Toxicol. Sci., September 1, 2006; 93(1): 213 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. P. James, E. M. Alonso, L. S. Hynan, J. A. Hinson, T. J. Davern, W. M. Lee, R. H. Squires, and the Pediatric Acute Liver Failure Study Group Detection of Acetaminophen Protein Adducts in Children With Acute Liver Failure of Indeterminate Cause Pediatrics, September 1, 2006; 118(3): e676 - e681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Njoku, J. L. Mellerson, M. V. Talor, D. R. Kerr, N. R. Faraday, I. Outschoorn, and N. R. Rose Role of CYP2E1 Immunoglobulin G4 Subclass Antibodies and Complement in Pathogenesis of Idiosyncratic Drug-Induced Hepatitis Clin. Vaccine Immunol., February 1, 2006; 13(2): 258 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L E Schmidt Age and paracetamol self-poisoning Gut, May 1, 2005; 54(5): 686 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T T Knudsen, S Thorsen, S A Jensen, K Dalhoff, L E Schmidt, U Becker, and F Bendtsen Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects Gut, April 1, 2005; 54(4): 515 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tung, E. M. Yoshida, C. S. K. Wang, and U. P. Steinbrecher Severe desflurane hepatotoxicity after colon surgery in an elderly patient: [Severe hepatotoxicite au desflurane apres une operation du colon chez une patiente agee] Can J Anesth, February 1, 2005; 52(2): 133 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Lee and J. R. Senior Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions Toxicol Pathol, January 1, 2005; 33(1): 155 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Guo, J. S. Moffit, C. J. Nicol, J. M. Ward, L. A. Aleksunes, A. L. Slitt, S. A. Kliewer, J. E. Manautou, and F. J. Gonzalez Enhanced Acetaminophen Toxicity by Activation of the Pregnane X Receptor Toxicol. Sci., December 1, 2004; 82(2): 374 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hawton, S. Simkin, J. Deeks, J. Cooper, A. Johnston, K. Waters, M. Arundel, W. Bernal, B. Gunson, M. Hudson, et al. UK legislation on analgesic packs: before and after study of long term effect on poisonings BMJ, November 6, 2004; 329(7474): 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Greenberger and P. Sharma Update in Gastroenterology and Hepatology Ann Intern Med, September 7, 2004; 141(5): 374 - 380. [Full Text] [PDF]
|
|
|
|
|
|
G. E Sklar and M. Subramaniam Acetylcysteine Treatment for Non-Acetaminophen-Induced Acute Liver Failure Ann. Pharmacother., March 1, 2004; 38(3): 498 - 501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Schears Acute Liver Failure in the United States Ann Intern Med, December 16, 2003; 139(12): 1045 - 1045. [Full Text] [PDF]
|
|
|
|
|
|
W. D. Carey Acute Liver Failure in the United States Ann Intern Med, December 16, 2003; 139(12): 1044 - 1045. [Full Text] [PDF]
|
|
|
|
|
|
J. Marrero, F. J. Martinez, and R. Hyzy Advances in Critical Care Hepatology Am. J. Respir. Crit. Care Med., December 15, 2003; 168(12): 1421 - 1426. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Graham Risk of Unexplained Acute Liver Failure in Diabetes Mellitus Arch Intern Med, November 24, 2003; 163(21): 2649 - 2650. [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Bliss, R. H. Moseley, J. Del Valle, and S. Saint A Window of Opportunity N. Engl. J. Med., November 6, 2003; 349(19): 1848 - 1853. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Estes, D. Stolpman, A. Olyaei, C. L. Corless, J. M. Ham, J. M. Schwartz, and S. L. Orloff High Prevalence of Potentially Hepatotoxic Herbal Supplement Use in Patients With Fulminant Hepatic Failure Arch Surg, August 1, 2003; 138(8): 852 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Lee Drug-Induced Hepatotoxicity N. Engl. J. Med., July 31, 2003; 349(5): 474 - 485. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
